Johnson & Johnson News
Eli Lilly and partner Boehringer Ingelheim's empagliflozin received Complete Response Letter (CRL)
A family's lung disease defies antibacterial antibiotics and serves as a reminder of the risk to particular outdoor workers as Spring approaches. Even Johnny Cash knew.
The FIFA World Cup 2014 will provide marketers with a dream opportunity to push their brands as four billion fans are expected to tune in on television and a multitude of digital and social media channels.
Eli Lilly and Co and partner Boehringer Ingelheim said U.S. regulators have declined to approve their experimental diabetes drug empagliflozin, citing previously observed problems at a facility where it would be made. The drugmakers, in a joint release on Wednesday, said the U.S. Food and Drug Administration determined that issues at the Boehringer factory in Ingelheim, Germany, need to be resolved before the product could be approved. Lilly and privately held Boehringer said the FDA had not asked for new clinical trials of the diabetes drug. The drug is a member of a new class of diabetes medicines known as SGLT2 inhibitors, which block the kidney from reabsorbing blood sugar, thereby spurring removal of glucose through the urine.
US stocks soared on Tuesday as fears of confrontation between Russia and Ukraine subsided
Bull of the Day: Quintiles (Q) - Bull of the Day